{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T05:08:44Z","timestamp":1782364124227,"version":"3.54.5"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019637","name":"Horizon Therapeutics PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019637","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The Feline McDonough sarcoma-like tyrosine kinase 3 (FLT3)\/FLT3 ligand (FLT3L) pathway is associated with pathogenesis of several autoimmune diseases, including Sj\u00f6gren\u2019s. Inflammatory signals increase FLT3L levels; FLT3L signaling promotes further inflammation through the differentiation, function, and survival of immune cells, including dendritic cells (DCs), monocytes, and B cells. Patients with Sj\u00f6gren\u2019s have elevated FLT3L levels, increased infiltration of DCs, macrophages, and B cells into salivary glands and tertiary lymphoid structures (TLS). We hypothesized that therapeutically neutralizing FLT3L may reduce inflammatory manifestations in the NOD.H2h4 spontaneous Sj\u00f6gren\u2019s mouse model. Female mice aged 15 to 17\u2009wk, an age at which features of Sj\u00f6gren\u2019s have developed, were administered an anti-mouse FLT3L monoclonal antibody or isotype control for 8\u2009wk. Compared with control, anti-FLT3L antibody treatment significantly reduced free serum FLT3L, splenic DC numbers, T cell activation, and salivary gland TLS (P\u2009&amp;lt;\u20090.05 for all). Neutralizing FLT3L may effectively treat Sj\u00f6gren\u2019s and other FLT3L-associated autoimmune diseases.<\/jats:p>","DOI":"10.1093\/jimmun\/vkaf220","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T18:36:23Z","timestamp":1756924583000},"page":"2557-2563","source":"Crossref","is-referenced-by-count":2,"title":["FLT3L neutralization reduces dendritic cell numbers, T Cell activation, and salivary gland lymphocyte infiltration in the NOD.H2h4 Sj\u00f6gren\u2019s mouse model"],"prefix":"10.1093","volume":"214","author":[{"given":"Agata","family":"Bartczak","sequence":"first","affiliation":[{"name":"Research and Medical Affairs, Amgen Inc , Thousand Oaks, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Sims","sequence":"additional","affiliation":[{"name":"Research, AstraZeneca , Gaithersburg, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamelia","family":"Zerrouki","sequence":"additional","affiliation":[{"name":"Research and Medical Affairs, Amgen Inc , Thousand Oaks, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6672-5918","authenticated-orcid":false,"given":"Brian","family":"Naiman","sequence":"additional","affiliation":[{"name":"Research, AstraZeneca , Gaithersburg, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariful","family":"Qadri","sequence":"additional","affiliation":[{"name":"Research, AstraZeneca , Gaithersburg, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M","family":"Hansen","sequence":"additional","affiliation":[{"name":"Research, AstraZeneca , Gaithersburg, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-1347","authenticated-orcid":false,"given":"Annie","family":"Lau-Kilby","sequence":"additional","affiliation":[{"name":"Research and Medical Affairs, Amgen Inc , Thousand Oaks, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"2025103103524877500_vkaf220-B1","doi-asserted-by":"crossref","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","article-title":"Sj\u00f6gren syndrome","volume":"2","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025103103524877500_vkaf220-B2","first-page":"2044","article-title":"Serological implications of germinal center-like structures in primary Sj\u00f6gren\u2019s syndrome","volume":"34","author":"Jonsson","year":"2007","journal-title":"J Rheumatol"},{"key":"2025103103524877500_vkaf220-B3","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/imcb.12484","article-title":"Dendritic cell Flt3 - regulation, roles and repercussions for immunotherapy","volume":"99","author":"Wilson","year":"2021","journal-title":"Immunol Cell Biol"},{"key":"2025103103524877500_vkaf220-B4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2249.2009.04071.x","article-title":"Decrease of blood dendritic cells and increase of tissue-infiltrating dendritic cells are involved in the induction of Sj\u00f6gren\u2019s syndrome but not in the maintenance","volume":"159","author":"Ozaki","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"2025103103524877500_vkaf220-B5","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1002\/art.38129","article-title":"Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sj\u00f6gren\u2019s syndrome","volume":"65","author":"Tob\u00f3n","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025103103524877500_vkaf220-B6","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41586-020-2436-0","article-title":"FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease","volume":"584","author":"Saevarsdottir","year":"2020","journal-title":"Nature"},{"key":"2025103103524877500_vkaf220-B7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/annrheumdis-2021-221754","article-title":"Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset","volume":"81","author":"Saevarsdottir","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2025103103524877500_vkaf220-B8","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol Rev"},{"key":"2025103103524877500_vkaf220-B9","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood.V97.4.1027","article-title":"Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor gamma-chain signaling and inhibited by cyclosporin A","volume":"97","author":"Chklovskaia","year":"2001","journal-title":"Blood"},{"key":"2025103103524877500_vkaf220-B10","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1002\/art.27611","article-title":"The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sj\u00f6gren\u2019s syndrome","volume":"62","author":"Tob\u00f3n","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025103103524877500_vkaf220-B11","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1016\/j.cell.2024.04.009","article-title":"FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice","volume":"187","author":"Momenilandi","year":"2024","journal-title":"Cell"},{"key":"2025103103524877500_vkaf220-B12","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/jcp.24824","article-title":"Flt3 ligand induces monocyte proliferation and enhances the function of monocyte-derived dendritic cells in vitro","volume":"230","author":"Kim","year":"2015","journal-title":"J Cell Physiol"},{"key":"2025103103524877500_vkaf220-B13","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3390\/cancers13071525","article-title":"The Flt3L\/Flt3 axis in dendritic cell biology and cancer immunotherapy","volume":"13","author":"Cueto","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025103103524877500_vkaf220-B14","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/sj.leu.2404532","article-title":"Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease","volume":"21","author":"Baldwin","year":"2007","journal-title":"Leukemia"},{"key":"2025103103524877500_vkaf220-B15","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.immuni.2008.10.012","article-title":"Lack of conventional dendritic cells is compatible with normal development and T cell homeostasis, but causes myeloid proliferative syndrome","volume":"29","author":"Birnberg","year":"2008","journal-title":"Immunity"},{"key":"2025103103524877500_vkaf220-B16","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/sj.cgt.7701018","article-title":"Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection","volume":"14","author":"Solheim","year":"2007","journal-title":"Cancer Gene Ther"},{"key":"2025103103524877500_vkaf220-B17","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood.V95.11.3489","article-title":"Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells","volume":"95","author":"McKenna","year":"2000","journal-title":"Blood"},{"key":"2025103103524877500_vkaf220-B18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ni.1615","article-title":"The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues","volume":"9","author":"Waskow","year":"2008","journal-title":"Nat Immunol"},{"key":"2025103103524877500_vkaf220-B19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/1529-0131(200102)44:2<419::AID-ANR61>3.0.CO;2-U","article-title":"Alteration of peripheral blood dendritic cells in patients with primary Sjogren\u2019s syndrome","volume":"44","author":"Ozaki","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2025103103524877500_vkaf220-B20","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1749-6632.2009.04760.x","article-title":"Sex differences in a murine model of Sj\u00f6gren\u2019s syndrome","volume":"1173","author":"Cih\u00e1kov\u00e1","year":"2009","journal-title":"Ann NY Acad Sci"},{"key":"2025103103524877500_vkaf220-B21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.molimm.2014.05.006","article-title":"Discerning the kinetics of autoimmune manifestations in a model of Sj\u00f6gren\u2019s syndrome","volume":"62","author":"Karnell","year":"2014","journal-title":"Mol Immunol"},{"key":"2025103103524877500_vkaf220-B22","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1084\/jem.178.3.793","article-title":"I-E+ nonobese diabetic mice develop insulitis and diabetes","volume":"178","author":"Podolin","year":"1993","journal-title":"J Exp Med"},{"key":"2025103103524877500_vkaf220-B23","doi-asserted-by":"crossref","first-page":"11179","DOI":"10.3390\/ijms241311179","article-title":"Outline of salivary gland pathogenesis of Sjogren\u2019s syndrome and current therapeutic approaches","volume":"24","author":"Yura","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025103103524877500_vkaf220-B24","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.20998","article-title":"Activation of the type I interferon system in primary Sjogren\u2019s syndrome: a possible etiopathogenic mechanism","volume":"52","author":"Bave","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025103103524877500_vkaf220-B25","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.2174\/138920112802273290","article-title":"Primary Sjogren\u2019s syndrome and the type I interferon system","volume":"13","author":"Nordmark","year":"2012","journal-title":"Curr Pharm Biotechnol"},{"key":"2025103103524877500_vkaf220-B26","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI28508","article-title":"The IL-23\/IL-17 axis in inflammation","volume":"116","author":"Iwakura","year":"2006","journal-title":"J Clin Invest"},{"key":"2025103103524877500_vkaf220-B27","doi-asserted-by":"crossref","first-page":"187258","DOI":"10.1155\/2012\/187258","article-title":"Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"2012","author":"Mieliauskaite","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"2025103103524877500_vkaf220-B28","doi-asserted-by":"crossref","first-page":"102418","DOI":"10.1016\/j.jaut.2020.102418","article-title":"Correction of autophagy impairment inhibits pathology in the NOD.H-2h4 mouse model of primary Sj\u00f6gren\u2019s syndrome","volume":"108","author":"Voynova","year":"2020","journal-title":"J Autoimmun"},{"key":"2025103103524877500_vkaf220-B29","doi-asserted-by":"crossref","first-page":"361ra137","DOI":"10.1126\/scitranslmed.aag0367","article-title":"Autoimmune manifestations in aged mice arise from early-life immune dysregulation","volume":"8","author":"Mahmoud","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025103103524877500_vkaf220-B30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/annrheumdis-2023-eular.7074","article-title":"LB0003 Dazodalibep (VIB4920\/HZN4920) in Sj\u00f6gren\u2019s subjects with an unacceptable symptom burden: safety and efficacy from a phase 2, randomized, double-blind study","volume":"82","author":"St Clair","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025103103524877500_vkaf220-B31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2023-eular.7074","article-title":"OP0143 Efficacy and safety of dazodalibep (VIB4920\/HZN4920) in subjects with Sj\u00f6gren\u2019s syndrome: a phase 2, randomized, double-blind, placebo-controlled, proof of concept study","volume":"82","author":"St Clair","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025103103524877500_vkaf220-B32","article-title":"A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of AMG 329, a monoclonal antibody, in conventional and plasmacytoid dendritic cell-mediated rheumatic diseases [abstract]","volume":"76","author":"Kivitz","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/10\/2557\/64202517\/vkaf220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/214\/10\/2557\/64202517\/vkaf220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:52:59Z","timestamp":1761897179000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/214\/10\/2557\/8247273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":32,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,9,3]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jimmun\/vkaf220","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,3]]}}}